MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

BACKGROUND & AIMS: Inhibitors of MET have not produced satisfactory outcomes in trials of patients with liver cancer. We investigated the mechanisms of liver tumor resistance to MET inhibitors in mice. METHODS: We tested the effects of MET inhibitors tivantinib and capmatinib in the mouse hepato...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gastroenterology
Main Authors: Li, Hui, Li, Chia-Wei, Li, Xiaoqiang, Ding, Qingqing, Guo, Lei, Liu, Shuang, Liu, Chunxiao, Lai, Chien-Chen, Hsu, Jung-Mao, Dong, Qiongzhu, Xia, Weiya, Hsu, Jennifer L., Yamaguchi, Hirohito, Du, Yi, Lai, Yun-Ju, Sun, Xian, Koller, Paul B., Ye, Qinghai, Hung, Mien-Chie
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6904924/
https://ncbi.nlm.nih.gov/pubmed/30711629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.gastro.2019.01.252
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados